Wustrow T P, Wendt T G, Schalhorn A
Klinik und Poliklinik für Hals-Nasen-Ohrenkranke, Ludwig-Maximilians-Universität.
Laryngol Rhinol Otol (Stuttg). 1988 Nov;67(11):567-75.
Sixty untreated patients with advanced carcinoma of the head and neck (stages III = 11 and IV = 49) were treated simultaneously with three cycles of polychemotherapy and radiation. Chemotherapy consisted of cisplatinum (DDP) 60 mg/m2 after prehydration with saline and mannitol, 5-fluorouracil (5-FU) 350 mg/m2 and folinic acid (FA) 50 mg/m2 on day 2 as a bolus and a continuous infusion of 5-FU 350 mg/m2/24 h and folinic acid (FA) 100 mg/m2/24 h from day 2-5. Concomitantly, accelerated hyperfractionated radiation was administered from day 3-11. Two fractions per day with 1.8 Gy each were given, 13 fractions in 9 days. This cycle was repeated two times on day 22 and 44 with an interval without treatment from day 16-21 and 34-43. Total radiation dose was 70.2 Gy in 51 days. Acute toxicities (WHO grade II and III) consisted mainly of leucopenia (75%), thrombopenia (15%), weight loss (mean 5.8 +/- 3.7%) and mucositis (66%). Grade IV was never reached. Except for 3 patients, who died during treatment due to fatal tumor bleeding or carotid rupture, all were able to finish the treatment with reduction in chemotherapy in only 95% (DDP) and 98% (5-FU) with no changes in the radiation protocol. Evaluation of tumor response at 3 months after end of treatment showed 68% complete and 32% partial responses. 5 patients developed distant metastases. Survival with local control after 12 months was 80.8% and 71.3% after 24 months. 1 and 2 years disease-free survival was 70.8% and 62.1%. Total survival irrespective of cause of death was 77.9% and 57.2% after 1 and 2 years. This particular simultaneous radio-polychemotherapy protocol appears to be well tolerable and highly effective in terms of tumor control and survival of advanced stages of head and neck cancer.
60例未经治疗的晚期头颈癌患者(Ⅲ期11例,Ⅳ期49例)接受了三个周期的多药化疗与放疗同步治疗。化疗方案为:在使用生理盐水和甘露醇进行预水化后,给予顺铂(DDP)60mg/m²,第2天给予5-氟尿嘧啶(5-FU)350mg/m²和亚叶酸(FA)50mg/m²静脉推注,随后从第2天至第5天持续静脉输注5-FU 350mg/m²/24h和亚叶酸(FA)100mg/m²/24h。同时,从第3天至第11天进行加速超分割放疗。每天给予2次分割剂量,每次1.8Gy,9天内共13次分割剂量。该周期在第22天和第44天重复两次,第16天至第21天以及第34天至第43天为无治疗间隔期。51天内总放疗剂量为70.2Gy。急性毒性反应(WHOⅡ级和Ⅲ级)主要包括白细胞减少(75%)、血小板减少(15%)、体重减轻(平均5.8±3.7%)和黏膜炎(66%)。未出现Ⅳ级毒性反应。除3例患者在治疗期间因致命性肿瘤出血或颈动脉破裂死亡外,所有患者均能够完成治疗,化疗剂量仅分别减少95%(DDP)和98%(5-FU),放疗方案未改变。治疗结束3个月时评估肿瘤反应,显示完全缓解率为68%,部分缓解率为32%。5例患者发生远处转移。12个月时局部控制后的生存率为80.8%,24个月时为71.3%。1年和2年无病生存率分别为70.8%和62.1%。无论死因如何,1年和2年总生存率分别为77.9%和57.2%。这种特定的同步放化疗方案在晚期头颈癌的肿瘤控制和生存方面似乎耐受性良好且疗效显著。